Clovis Oncology 10K 2014 Annual report | CLVSQ Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Acea, automated, avitinib, bifurcation, Bio, Breakthrough, commensurate, default, Department, depressed, diminishing, doubt, expressly, faster, feature, Forty, France, GLOBOCAN, GMP, grace, Ib, indenture, Inspector, intensify, interaction, internet, Justice, lesion, levatinib, Lynparza, LynparzaTM, Mellon, modified, molecularly, nintedanib, perception, poziotinib, Prime, quotation, rank, recapitalizing, redeem, redeemed, redemption, refinance, refund, repay, repayment, rociletinib, RUCAPANC, screening, sinking, stringent, subordinated, talazoparib, therascreen, timeline, Topic, Trust, trustee, unamortized, unapproved, unsecured, waived, York

Removed: AICPA, Aid, anaplastic, arm, avoid, biology, bronchioalveolar, capitalization, CDER, cGCP, chance, characteristic, characterized, choose, choosing, collection, Combine, comment, COMP, complement, consummation, correlation, curve, deduction, define, deriving, devise, doubled, downgrade, draft, DSMB, dug, economically, Edition, effectuated, examine, finalized, flexibility, generation, geographic, GLP, house, imminent, implanted, initiating, intestinal, line, linking, measuring, modestly, Morgan, network, opposed, orally, organ, outsource, PAR, paragraph, partnered, partnering, pathologic, poor, positioning, practicing, premise, prescribed, prioritize, Project, Qualifying, recently, recognizing, recurrence, regression, responded, responsive, retrospectively, reverse, secondary, Shinoharashinsha, spare, split, stable, stratified, streamlined, subdivided, Suisse, superior, surrogate, Teva, thereunder, track, traditionally, transitioned, unaware, underwriting, undesired, unique, uniquely, USA, variation, vested, warrant, weight, white, wholly, xenograft

Clovis Oncology (CLVSQ) 10-K2014 FY Annual report

Content analysis